http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
원발성 중추신경계 림프종의 치료 성적에 대한 다기관 후향적 분석
문준호 ( Joon Ho Moon ),김동환 ( Dong hwan Kim ),안병민 ( Byung Min Ahn ),김시내 ( Shi Nae Kim ),전석봉 ( Seok Bong Jeon ),백진호 ( Jin Ho Baek ),김종광 ( Jong Gwang Kim ),손상균 ( Sang Kyun Sohn ),이규보 ( Kyu Bo Lee ),황정현 ( J 대한내과학회 2006 대한내과학회지 Vol.71 No.6
Background: A primary central nervous system lymphoma (PCNSL) is a rare neoplasm with a poor prognosis. The treatment of PCNSL involves a combination of chemotherapy, intrathecal chemotherapy and radiotherapy. This study retrospectively evaluated the treatment outcomes and prognostic factors of Korean patients with PCNSL. Methods: Between 1995 and 2003, 58 patients diagnosed with PCNSL from the multi-center hospitals were enrol1ed in this study. Among 56 patients who had received treatment, 16 patients were treated with radiotherapy alone, while 40 patients were treated with combined chemotherapy (CHOP; 9 cases, high-dose methotrexate; 31 cases) and radiotherapy. Results: The median age of the patients was 58 years (range, 19-76). A diffuse large B-cell lymphoma was diagnosed in 56 cases (96.6%), while a peripheral T-cell lymphoma was diagnosed in 2 cases. Of the 47 patients who could be assessed for their response after treatment, a CR and PR was observed in 32 (68%) and 11 patients (23%), respectively, giving an overall response rate of 91% (95% CI, 82~100%). The estimated 3-year overall survival rate for all the patients was 67±7.9% and the 3-year disease free survival rate was 53±8.3%. The overall survival of the high-dose methotrexate group was superior to that of the CHOP group (77±10%) versus 47±19%, p=0.05). Leukoencephalopathy was observed as a late complication in 9 patients (21%). No significant prognostic factors affecting survival were found by univariate analysis. Conclusions: Approximately half of the patients could have long-term survival after treatment in this study. High-dose methotrexate containing chemotherapy followed by radiotherapy was found to be an effective treatment. (Korean J Med 71:65i4-661, 2000)